Application of PAR2 coupled TRPV3 mediated IL33 release in AD treatment

The invention belongs to the technical field of medicines, and particularly relates to application of PAR2 coupled TRPV3 mediated IL33 release in AD treatment. According to the application, phosphorylation of CAMKII and JNK kinase in epidermis is inhibited by knocking out TRPV3, expression of interl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	YUAN XIAOHUI, JING MIAO, ZHOU LINGXUAN, WANG CHENYU, ZHAO JIAHUI
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention belongs to the technical field of medicines, and particularly relates to application of PAR2 coupled TRPV3 mediated IL33 release in AD treatment. According to the application, phosphorylation of CAMKII and JNK kinase in epidermis is inhibited by knocking out TRPV3, expression of interleukin 33 is further reduced, and AD is treated and relieved. Meanwhile, based on the pathway mechanism, the invention further provides a method for screening potential drugs for AD, and the method comprises the following steps: constructing an AD animal model and culturing primary keratinocytes; a drug to be detected acts on primary keratinocytes, and whether the drug is a potential therapeutic drug for AD or not is judged by detecting the expression condition of IL33 before and after the drug acts. The invention is of great significance to research and development and clinical diagnosis and treatment of AD related target inhibition drugs. 本发明属于医药技术领域，具体涉及一种PAR2偶联TRPV3介导IL33释放在AD治疗中的应用。本发明通过敲除TRPV3进而抑制表皮中CAMKⅡ及JNK激